This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Andrew Bellinger, MD, PhD
Chief Scientific Officer at Verve Therapeutics


Dr. Andrew Bellinger is the chief scientific officer at Verve Therapeutics. He is a cardiologist and scientist who specializes in company creation and growth, building high-performing research and development teams, translational medicine, drug delivery, and has a particular interest in the clinical development of novel classes of therapies. Prior to joining Verve, Andrew co-founded and served as chief scientific officer of Lyndra Therapeutics, and prior to that he was the chief scientific officer of Cocoon Biotech. He is also a co-founder of Corner Therapeutics. He previously practiced as an attending cardiologist at Brigham and Women’s Hospital and is board-certified in cardiovascular medicine and internal medicine.

Andrew holds an M.D., a Ph.D., and an MPhil from Columbia University, an M.S. in mathematics from New York University, and an A.B. in physics from Princeton University. He completed his clinical training in internal medicine at the University of California, San Francisco, and his clinical training in cardiology at Brigham and Women’s Hospital. He completed his postdoctoral research training in drug delivery with Dr. Robert Langer at the Massachusetts Institute of Technology.

Agenda Sessions

  • Proof-of-concept for in vivo Base Editing to Inactivate the PCSK9 Gene and Lower LDL-Cholesterol in Humans